title: The ABCD's of 5'-adenosine monophosphate-activated protein kinase and adrenoleukodystrophy.
abstract: This Editorial highlights a study by Singh and coworkers in the current issue of Journal of Neurochemistry, in which the authors present additional evidence that AMPKα1 is reduced in X-linked adrenoleukodystrophy (X-ALD). They make a case for increasing AMPKα1 activity for therapeutic purposes in this disease, and indicate how this goal may be achieved. Read the highlighted article 'Metformin-induced mitochondrial function and ABCD2 up regulation in X-linked adrenoleukodystrophy involves AMP activated protein kinase' on page 86.
authors.affiliation: University of Kansas Alzheimer's Disease Center, Kansas City, Kansas, USA.|Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas, USA.
authors.forename: Ian
authors.initials: I
authors.lastname: Weidling
authors.affiliation: University of Kansas Alzheimer's Disease Center, Kansas City, Kansas, USA.|Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas, USA.|Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.|Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.
authors.forename: Russell H
authors.initials: RH
authors.lastname: Swerdlow
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000326:Adrenoleukodystrophy / Q000201:enzymology*; D006801:Humans; D010766:Phosphorylation
chemical_list: D018528:ATP-Binding Cassette Transporters; D055372:AMP-Activated Protein Kinases